In Vivo Imaging for Assessing Receptor Status in Breast Cancer.
作者信息
Yeh Randy, D'Andrea Gabriella
机构信息
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 77, New York, NY 10065.
Department of Radiology, Weill Cornell Medical College, New York, NY.
出版信息
Radiology. 2025 Aug;316(2):e243832. doi: 10.1148/radiol.243832.
Abstract
摘要
相似文献
1
In Vivo Imaging for Assessing Receptor Status in Breast Cancer.用于评估乳腺癌受体状态的体内成像
Radiology. 2025 Aug;316(2):e243832. doi: 10.1148/radiol.243832.
2
Diagnostic performance of MRI for assessing axillary lymph node status after neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.MRI 评估乳腺癌新辅助化疗后腋窝淋巴结状态的诊断性能：系统评价和荟萃分析。
Eur Radiol. 2024 Feb;34(2):930-942. doi: 10.1007/s00330-023-10155-8. Epub 2023 Aug 24.
3
The development and validation of a risk stratification system for assessing axillary status after neoadjuvant therapy in node-positive breast cancer: a multicenter, prospective, observational study.用于评估新辅助治疗后淋巴结阳性乳腺癌腋窝状态的风险分层系统的开发与验证：一项多中心、前瞻性、观察性研究
Int J Surg. 2025 Jun 1;111(6):3731-3741. doi: 10.1097/JS9.0000000000002391. Epub 2025 May 12.
4
Prediction model for assessing HER2 status patient with invasive ductal carcinoma based on clinical parameters and ultrasound features: a dual-center study.基于临床参数和超声特征评估浸润性导管癌患者HER2状态的预测模型：一项双中心研究
BMC Womens Health. 2025 Jul 3;25(1):291. doi: 10.1186/s12905-025-03828-7.
5
[Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study.用于靶向Trop2的单光子发射计算机断层显像（SPECT）成像的锝[Tc]Tc-MY6349探针：从临床前研究到初步临床研究
J Nucl Med. 2025 Apr 1;66(4):543-551. doi: 10.2967/jnumed.124.268564.
6
MRI-based habitat analysis for Intratumoral heterogeneity quantification combined with deep learning for HER2 status prediction in breast cancer.基于磁共振成像的肿瘤内异质性定量栖息地分析结合深度学习预测乳腺癌人表皮生长因子受体2状态
Magn Reson Imaging. 2025 Oct;122:110429. doi: 10.1016/j.mri.2025.110429. Epub 2025 May 23.
7
Diagnostic accuracy and safety of 16α-[F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.16α-[F]氟-17β-雌二醇 PET-CT 评估乳腺癌复发或转移病灶中雌激素受体状态的诊断准确性和安全性：一项前瞻性队列研究。
Lancet Oncol. 2019 Apr;20(4):546-555. doi: 10.1016/S1470-2045(18)30936-7. Epub 2019 Mar 4.
8
Assessing the Efficacy of Current Histopathological Tumor Reporting Systems for Evaluating the Response to Neoadjuvant Chemotherapy for Breast Carcinoma: Protocol for an Observational Study.评估当前组织病理学肿瘤报告系统对评估乳腺癌新辅助化疗反应的疗效：一项观察性研究方案。
JMIR Res Protoc. 2025 Jun 16;14:e56825. doi: 10.2196/56825.
9
Abbreviated and Ultrafast Dynamic Contrast-enhanced (DCE) MR Imaging.简化及超快动态对比增强（DCE）磁共振成像
Magn Reson Med Sci. 2025 Jul 1;24(3):315-331. doi: 10.2463/mrms.rev.2024-0158. Epub 2025 Mar 5.
10
Magnetic resonance imaging-based radiomics was used to evaluate the level of prognosis-related immune cell infiltration in breast cancer tumor microenvironment.基于磁共振成像的放射组学用于评估乳腺癌肿瘤微环境中与预后相关的免疫细胞浸润水平。
BMC Med Imaging. 2024 Feb 2;24(1):31. doi: 10.1186/s12880-024-01212-9.
本文引用的文献
1
First-in-Human Evaluation of Site-Specifically Labeled Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.首例人体试验：特异性标记的 Zr-曲妥珠单抗在人表皮生长因子受体 2 阳性乳腺癌患者中的应用
J Nucl Med. 2024 Mar 1;65(3):386-393. doi: 10.2967/jnumed.123.266392.
2
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.人表皮生长因子受体 2（HER2）过表达的原发性乳腺癌转移部位 HER2 表达缺失。
J Clin Oncol. 2012 Feb 20;30(6):593-9. doi: 10.1200/JCO.2010.33.8889. Epub 2011 Nov 28.
Zotero 插件